Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion

(2013) E. Lengline et al.   HAEMATOLOGICA

Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement

(2012) Maryam Arefi et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome

(2012) A Pardanani et al.   LEUKEMIA

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients

(2008) Grzegorz Helbig et al.   BRITISH JOURNAL OF HAEMATOLOGY

Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders

(2008) Genevieve Gallagher et al.   CANCER GENETICS AND CYTOGENETICS

Identification of aMYO18A-PDGFRBfusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2)

(2008) Christoph Walz et al.   GENES CHROMOSOMES & CANCER